menu
    • menu
    [{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Treosulfan","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Medexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Medexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"medac","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Treosulfan","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Medexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medexus Pharmaceuticals \/ Medac","highestDevelopmentStatusID":"15","companyTruncated":"Medexus Pharmaceuticals \/ Medac"},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"medac","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Treosulfan","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Medexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medexus Pharmaceuticals \/ Medac","highestDevelopmentStatusID":"15","companyTruncated":"Medexus Pharmaceuticals \/ Medac"},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"medac","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Treosulfan","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Medexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medexus Pharmaceuticals \/ Medac","highestDevelopmentStatusID":"15","companyTruncated":"Medexus Pharmaceuticals \/ Medac"},{"orgOrder":0,"company":"medac","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2021","type":"Licensing Agreement","leadProduct":"Treosulfan","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"medac \/ Medexus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"medac \/ Medexus Pharmaceuticals"},{"orgOrder":0,"company":"medac","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2021","type":"Licensing Agreement","leadProduct":"Treosulfan","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"medac \/ Medexus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"medac \/ Medexus Pharmaceuticals"},{"orgOrder":0,"company":"medac","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2024","type":"Licensing Agreement","leadProduct":"Treosulfan","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"medac \/ Medexus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"medac \/ Medexus Pharmaceuticals"},{"orgOrder":0,"company":"medac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Treosulfan","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"medac \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"medac \/ Inapplicable"},{"orgOrder":0,"company":"medac","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Treosulfan","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"medac \/ Syneos Health","highestDevelopmentStatusID":"15","companyTruncated":"medac \/ Syneos Health"}]

    Find Clinical Drug Pipeline Developments & Deals for Treosulphan

    Menu

    Treosulphan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            medac

                            Germany
                            Contract Pharma
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Boothmedac CDMO: Tailored CDMO services for injectables in syringes, cartridges & vials – aseptic, reliable, flexible and a solution ahead.

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Strategic cornerstone: FDA approves treosulfan for alloHSCT

                            Details : Grafapex (treosulfan) is now approved by FDA for the treatment of adult and pediatric patients aged 1 year and older with acute myeloid leukemia.

                            Product Name : Grafapex

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            January 23, 2025

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            medac

                            Germany
                            Contract Pharma
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Boothmedac CDMO: Tailored CDMO services for injectables in syringes, cartridges & vials – aseptic, reliable, flexible and a solution ahead.

                            Lead Product(s) : Treosulfan

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Medexus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Medexus and medac Conclude Negotiations to Amend US Treosulfan Agreement

                            Details : The fourth amendment adjusts the unpaid regulatory milestone payments upon an FDA approval of Grafapex (treosulfan).

                            Product Name : Grafapex

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            December 02, 2024

                            Lead Product(s) : Treosulfan

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Medexus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            medac

                            Germany
                            Contract Pharma
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Boothmedac CDMO: Tailored CDMO services for injectables in syringes, cartridges & vials – aseptic, reliable, flexible and a solution ahead.

                            Lead Product(s) : Treosulfan

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            September 09, 2022

                            Lead Product(s) : Treosulfan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            medac

                            Germany
                            Contract Pharma
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Boothmedac CDMO: Tailored CDMO services for injectables in syringes, cartridges & vials – aseptic, reliable, flexible and a solution ahead.

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Medexus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Medexus Pharmaceuticals and medac GmbH enter into Licensing Agreement for First-in-Class Conditioning Agent, T...

                            Details : Treosulfan will be marketed in Canada under the brand name Trecondyv® and indicated in combination with fludarabine as part of a conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (“allo-HSCT”).

                            Product Name : Trecondyv

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            July 12, 2021

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Medexus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            medac

                            Germany
                            Contract Pharma
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Boothmedac CDMO: Tailored CDMO services for injectables in syringes, cartridges & vials – aseptic, reliable, flexible and a solution ahead.

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Medexus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Medexus and Medac Enter Into a License Agreement for Treosulfan, in the United States

                            Details : Medac intends to leverage its strong, existing commercial infrastructure in the United States to address the underserved allo-HSCT market through its commercialization of treosulfan.

                            Product Name : Trecondyv

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            February 02, 2021

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Medexus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            medac

                            Germany
                            Contract Pharma
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Boothmedac CDMO: Tailored CDMO services for injectables in syringes, cartridges & vials – aseptic, reliable, flexible and a solution ahead.

                            Lead Product(s) : Treosulfan

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Celerion | Venn Life Sciences | Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            January 29, 2015

                            Lead Product(s) : Treosulfan

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Celerion | Venn Life Sciences | Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            medac

                            Germany
                            Contract Pharma
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Boothmedac CDMO: Tailored CDMO services for injectables in syringes, cartridges & vials – aseptic, reliable, flexible and a solution ahead.

                            Lead Product(s) : Treosulfan

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Celerion | Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            January 07, 2015

                            Lead Product(s) : Treosulfan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Celerion | Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            medac

                            Germany
                            Contract Pharma
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Boothmedac CDMO: Tailored CDMO services for injectables in syringes, cartridges & vials – aseptic, reliable, flexible and a solution ahead.

                            Lead Product(s) : Treosulfan

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose-range Finding Treosulfan-based Conditioning

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            February 05, 2010

                            Lead Product(s) : Treosulfan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            medac

                            Germany
                            Contract Pharma
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Boothmedac CDMO: Tailored CDMO services for injectables in syringes, cartridges & vials – aseptic, reliable, flexible and a solution ahead.

                            Lead Product(s) : Treosulfan

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML)

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            February 05, 2010

                            Lead Product(s) : Treosulfan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            medac

                            Germany
                            Contract Pharma
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Boothmedac CDMO: Tailored CDMO services for injectables in syringes, cartridges & vials – aseptic, reliable, flexible and a solution ahead.

                            Lead Product(s) : Treosulfan

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS)

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            February 04, 2010

                            Lead Product(s) : Treosulfan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth